Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.

Diabetes care - 1 Nov 2022

Xu Min, Zheng Jie, Hou Tianzhichao, Lin Hong, Wang Tiange, Wang Shuangyuan, Lu Jieli, Zhao Zhiyun, Li Mian, Xu Yu, Ning Guang, Bi Yufang, Wang Weiqing

Abstract excerpt

OBJECTIVE: To investigate the causal role of choline metabolites mediating sodium-glucose cotransporter 2 (SGLT2) inhibition in coronary artery disease (CAD) and type 2 diabetes (T2D) using Mendelian randomization (MR). RESEARCH DESIGN AND METHODS: A two-sample two-step MR was used to determine 1) causal effects of SGLT2 inhibition on CAD and T2D; 2) causal effects of three choline metabolites, total choline,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Choline
Share to Coronary Artery Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Genome-Wide Association Study

Share to Glycine

Share to Mendelian Randomization Analysis

Share to Phosphatidylcholines

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 36161993
DOI: 10.2337/dc22-0323
PMCID: PMC9862376

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SGLT2 Inhibition, Choline Metabolites, and Cardiometabolic Diseases: A Mediation Mendelian Randomization Study.PMID 36161993Read ↗

SGLT2 inhibition, circulating biomarkers, and Alzheimer's disease: A Mendelian randomization study.Semantic proximity Read ↗

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study.Semantic proximity Read ↗

A stratified study of human blood metabolites and coronary artery diseases-A Mendelian randomization study.Semantic proximity Read ↗

Assessment of Causal Direction Between Gut Microbiota–Dependent Metabolites and Cardiometabolic Health: A Bidirectional Mendelian Randomization AnalysisSemantic proximity Read ↗

Deciphering the interplay between SGLT2 inhibition, CCL4, and angina pectoris: A Mendelian randomization study.Semantic proximity Read ↗

Exploring blood metabolites and thyroid disorders: a bidirectional mendelian randomization studySemantic proximity Read ↗

Plasma Glutaminyl-Peptide Cyclotransferase Mediates Glucosamine-Metabolism-Driven Protection Against Hypertension: A Mendelian Randomization Study.Semantic proximity Read ↗

Causal relationship between plasma metabolites and hypertension: A Mendelian randomization study.Semantic proximity Read ↗

Trimethylamine N-oxide and its precursors in relation to blood pressure: A mendelian randomization studySemantic proximity Read ↗

A Mendelian Randomization Study of Metabolite Profiles, Fasting Glucose, and Type 2 Diabetes.Semantic proximity Read ↗

SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Integrative metabolomics and genomics reveal molecular signatures for type 2 diabetes and its cardiovascular complications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.